|
1
|
El-Serag HB: Hepatocellular carcinoma:
Recent trends in the United States. Gastroenterology. 127(Suppl 1):
S27–S34. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ferlay J, Shin HR, Bray F, Forman D,
Mathers C and Parkin DM: Estimates of worldwide burden of cancer in
2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar
|
|
3
|
Jin F, Xiang YB and Gao YT: Cancer
survival in Shanghai, People's Republic of China. IARC Sci Publ.
145:37–50. 1998.
|
|
4
|
Lee HJ, Kim MS, Shin JM, Park TJ, Chung HM
and Baek KH: The expression patterns of deubiquitinating enzymes,
USP22 and Usp22. Gene Expr Patterns. 6:277–284. 2006. View Article : Google Scholar
|
|
5
|
Zhang XY, Varthi M, Sykes SM, Phillips C,
Warzecha C, Zhu W, Wyce A, Thorne AW, Berger SL and McMahon SB: The
putative cancer stem cell marker USP22 is a subunit of the human
SAGA complex required for activated transcription and cell-cycle
progression. Mol Cell. 29:102–111. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zhang XY, Pfeiffer HK, Thorne AW and
McMahon SB: USP22, an hSAGA subunit and potential cancer stem cell
marker, reverses the polycomb-catalyzed ubiquitylation of histone
H2A. Cell Cycle. 7:1522–1524. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Liu Y, Yang Y, Xu H and Dong X:
Implication of USP22 in the regulation of BMI-1, c-Myc, p16INK4a,
p14ARF, and cyclin D2 expression in primary colorectal carcinomas.
Diagn Mol Pathol. 19:194–200. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhang Y, Yao L, Zhang X, Ji H, Wang L, Sun
S and Pang D: Elevated expression of USP22 in correlation with poor
prognosis in patients with invasive breast cancer. J Cancer Res
Clin Oncol. 137:1245–1253. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Tang B, Tang F, Li B, Yuan S, Xu Q,
Tomlinson S, Jin J, Hu W and He S: High USP22 expression indicates
poor prognosis in hepatocellular carcinoma. Oncotarget.
6:12654–12667. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Atanassov BS, Evrard YA, Multani AS, Zhang
Z, Tora L, Devys D, Chang S and Dent SY: Gcn5 and SAGA regulate
shelterin protein turnover and telomere maintenance. Mol Cell.
35:352–364. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Atanassov BS and Dent SY: USP22 regulates
cell proliferation by deubiquitinating the transcriptional
regulator FBP1. EMBO Rep. 12:924–930. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Uren AG, Pakusch M, Hawkins CJ, Puls KL
and Vaux DL: Cloning and expression of apoptosis inhibitory protein
homologs that function to inhibit apoptosis and/or bind tumor
necrosis factor receptor-associated factors. Proc Natl Acad Sci
USA. 93:4974–4978. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yang D, Welm A and Bishop JM: Cell
division and cell survival in the absence of survivin. Proc Natl
Acad Sci USA. 101:15100–15105. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ambrosini G, Adida C and Altieri DC: A
novel anti-apoptosis gene, survivin, expressed in cancer and
lymphoma. Nat Med. 3:917–921. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Peters JM: The anaphase promoting
complex/cyclosome: A machine designed to destroy. Nat Rev Mol Cell
Biol. 7:644–656. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
16
|
Li Z, Pei XH, Yan J, Yan F, Cappell KM,
Whitehurst AW and Xiong Y: CUL9 mediates the functions of the 3M
complex and ubiquitylates survivin to maintain genome integrity.
Mol Cell. 54:805–819. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Connell CM, Colnaghi R and Wheatley SP:
Nuclear survivin has reduced stability and is not cytoprotective. J
Biol Chem. 283:3289–3296. 2008. View Article : Google Scholar
|
|
18
|
Glinsky GV: Death-from-cancer signatures
and stem cell contribution to metastatic cancer. Cell Cycle.
4:1171–1175. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Glinsky GV, Berezovska O and Glinskii AB:
Microarray analysis identifies a death-from-cancer signature
predicting therapy failure in patients with multiple types of
cancer. J Clin Invest. 115:1503–1521. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Widschwendter M, Fiegl H, Egle D,
Mueller-Holzner E, Spizzo G, Marth C, Weisenberger DJ, Campan M,
Young J, Jacobs I, et al: Epigenetic stem cell signature in cancer.
Nat Genet. 39:157–158. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
21
|
Glinsky GV: Genomic models of metastatic
cancer: Functional analysis of death-from-cancer signature genes
reveals aneuploid, anoikis-resistant, metastasis-enabling phenotype
with altered cell cycle control and activated Polycomb Group (PcG)
protein chromatin silencing pathway. Cell Cycle. 5:1208–1216. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sowa ME, Bennett EJ, Gygi SP and Harper
JW: Defining the human deubiquitinating enzyme interaction
landscape. Cell. 138:389–403. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Piao S, Ma J, Wang W, Liu Y, Zhang M, Chen
H and Guo F, Zhang B and Guo F: Increased expression of USP22 is
associated with disease progression and patient prognosis of
salivary duct carcinoma. Oral Oncol. 49:796–801. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ning J, Zhang J, Liu W, Lang Y, Xue Y and
Xu S: Overexpression of ubiquitin-specific protease 22 predicts
poor survival in patients with early-stage non-small cell lung
cancer. Eur J Histochem. 56:e462012. View Article : Google Scholar
|
|
25
|
Piao S, Liu Y, Hu J, Guo F, Ma J, Sun Y
and Zhang B: USP22 is useful as a novel molecular marker for
predicting disease progression and patient prognosis of oral
squamous cell carcinoma. PLoS One. 7:e425402012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Liu YL, Jiang SX, Yang YM, Xu H, Liu JL
and Wang XS: USP22 acts as an oncogene by the activation of
BMI-1-mediated INK4a/ARF pathway and Akt pathway. Cell Biochem
Biophys. 62:229–235. 2012. View Article : Google Scholar
|
|
27
|
Lin Z, Yang H, Kong Q, Li J, Lee SM, Gao
B, Dong H, Wei J, Song J, Zhang DD, et al: USP22 antagonizes p53
transcriptional activation by deubiquitinating Sirt1 to suppress
cell apoptosis and is required for mouse embryonic development. Mol
Cell. 46:484–494. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Honda R, Körner R and Nigg EA: Exploring
the functional interactions between Aurora B, INCENP, and survivin
in mitosis. Mol Biol Cell. 14:3325–3341. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Beardmore VA, Ahonen LJ, Gorbsky GJ and
Kallio MJ: Survivin dynamics increases at centromeres during G2/M
phase transition and is regulated by microtubule-attachment and
Aurora B kinase activity. J Cell Sci. 117:4033–4042. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Peroukides S, Bravou V, Alexopoulos A,
Varakis J, Kalofonos H and Papadaki H: Survivin overexpression in
HCC and liver cirrhosis differentially correlates with p-STAT3 and
E-cadherin. Histol Histopathol. 25:299–307. 2010.PubMed/NCBI
|
|
31
|
Morinaga S, Nakamura Y, Ishiwa N,
Yoshikawa T, Noguchi Y, Yamamoto Y, Rino Y, Imada T, Takanashi Y,
Akaike M, et al: Expression of survivin mRNA associates with
apoptosis, proliferation and histologically aggressive features in
hepatocellular carcinoma. Oncol Rep. 12:1189–1194. 2004.PubMed/NCBI
|
|
32
|
Qi G, Kudo Y, Ando T, Tsunematsu T,
Shimizu N, Siriwardena SB, Yoshida M, Keikhaee MR, Ogawa I and
Takata T: Nuclear Survivin expression is correlated with malignant
behaviors of head and neck cancer together with Aurora-B. Oral
Oncol. 46:263–270. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Qi G, Tuncel H, Aoki E, Tanaka S, Oka S,
Kaneko I, Okamoto M, Tatsuka M, Nakai S and Shimamoto F:
Intracellular localization of survivin determines biological
behavior in colorectal cancer. Oncol Rep. 22:557–562.
2009.PubMed/NCBI
|
|
34
|
Tuncel H, Shimamoto F, Kaneko Guangying Qi
H, Aoki E, Jikihara H, Nakai S, Takata T and Tatsuka M: Nuclear
Aurora B and cytoplasmic survivin expression is involved in lymph
node metastasis of colorectal cancer. Oncol Lett. 3:1109–1114.
2012.PubMed/NCBI
|
|
35
|
Hori M, Miki T, Okamoto M, Yazama F,
Konishi H, Kaneko H, Shimamoto F, Ota T, Temme A and Tatsuka M: The
detergent-soluble cytoplasmic pool of survivin suppresses anoikis
and its expression is associated with metastatic disease of human
colon cancer. PLoS One. 8:e557102013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Acquati S, Greco A, Licastro D, Bhagat H,
Ceric D, Rossini Z, Grieve J, Shaked-Rabi M, Henriquez NV, Brandner
S, et al: Epigenetic regulation of survivin by Bmi1 is cell type
specific during corticogenesis and in gliomas. Stem Cells.
31:190–202. 2013. View Article : Google Scholar
|
|
37
|
Bhattacharyya J, Mihara K, Ohtsubo M,
Yasunaga S, Takei Y, Yanagihara K, Sakai A, Hoshi M, Takihara Y and
Kimura A: Overexpression of BMI-1 correlates with drug resistance
in B-cell lymphoma cells through the stabilization of survivin
expression. Cancer Sci. 103:34–41. 2012. View Article : Google Scholar
|
